In particular, glioma patients with “Very Low” ANXA2 IHC score (< 25° percentile) show a significantly prolonged PFS and OS when compared with remaining “ANXA2 High” patients (Table 1 and Supplementary Figure S2A–S2D). The gene discussed is ANXA2; the disease is central nervous system cancer.